Molecular Imaging and Biology

, Volume 9, Issue 4, pp 204–216 | Cite as

The Application of Positron-Emitting Molecular Imaging Tracers in Alzheimer’s Disease

Review Article Special Issue: Molecular Imaging in the Evaluation of Neurodegenerative Diseases


The symptomatology and known pathology of Alzheimer's disease are restricted to the central nervous system. This review details studies of PET tracers aimed at interrogating cholinergic, serotonergic, opiate, benzodiazepine, and inflammatory pathways as well as PET tracers that illuminate amyloid plaques and neurofibrillary tangles in AD. Progress has been remarkable. Together with studies of brain structure with MRI and of functional regional brain activity, e.g., through measures of blood flow and glucose metabolic rate, molecular imaging promises to dramatically alter our understanding of the structural and physiological abnormalities underlying AD symptomatology. A more immediate impact on the diagnosis and treatment evaluation of AD patients in clinical trials is predicted while the possibility of personalized treatment or prevention of AD may not be that far away.

Key words

Brain imaging Cholinergic Opiate Amyloid Serotonin 


  1. 1.
    Bowen DM, et al. (1983) Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer’s disease. J Neurochem 41:266–272PubMedCrossRefGoogle Scholar
  2. 2.
    Davies P, Maloney AFJ (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2:1403PubMedCrossRefGoogle Scholar
  3. 3.
    Cross A (1990) Serotonin in Alzheimer-type dementia and other dementing illnesses. Ann N Y Acad Sci. 600:405–415PubMedCrossRefGoogle Scholar
  4. 4.
    Nitsch RM (1996) From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer’s disease. Neurodegeneration 5:477–482PubMedCrossRefGoogle Scholar
  5. 5.
    Nitsch RM, Deng M, Growdon JH, Wurtman RJ (1996) Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem 271:4188–4194PubMedCrossRefGoogle Scholar
  6. 6.
    Nitsch RM, Wurtman RJ, Growdon JH (1996) Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. Ann N Y Acad Sci 777:175–182PubMedCrossRefGoogle Scholar
  7. 7.
    Roberson MR, Harrell LE (1997) Cholinergic activity and amyloid precursor protein metabolism. Brain Res Brain Res Rev 25:50–69PubMedCrossRefGoogle Scholar
  8. 8.
    Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304–307PubMedCrossRefGoogle Scholar
  9. 9.
    Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184–185PubMedCrossRefGoogle Scholar
  10. 10.
    Coyle JT, Price PH, DeLong M (1983) Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219:1184–1189PubMedCrossRefGoogle Scholar
  11. 11.
    Beach TG, et al. (2000) The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol 59:308–313PubMedGoogle Scholar
  12. 12.
    Arendt T, Bigl V, Tennstedt A, Arendt A (1984) Correlation between cortical plaque count and neuronal loss in the nucleus basalis in Alzheimer’s disease. Neurosci Lett 48:81–85PubMedCrossRefGoogle Scholar
  13. 13.
    Sims NR, Bowen DM, Davison AN (1981) [14C]acetylcholine synthesis and [14C]carbon dioxide production from [U-14C]glucose by tissue prisms from human neocortex. Biochem J 196:867–876PubMedGoogle Scholar
  14. 14.
    Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL (1987) Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry 44:418–426PubMedGoogle Scholar
  15. 15.
    Beach TG, Honer WG, Hughes LH (1997) Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer’s disease? Acta Neuropathol (Berl) 93:146–153CrossRefGoogle Scholar
  16. 16.
    Davis BM, et al. (1985) Clinical studies of the cholinergic deficit in Alzheimer’s disease. I. Neurochemical and neuroendocrine studies. J Am Geriatr Soc 33:741–748PubMedGoogle Scholar
  17. 17.
    DeKosky ST, et al. (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:143–144CrossRefGoogle Scholar
  18. 18.
    Davis K, et al. (1999) Cholinergic markers in elderly patients with early signs of Alzheimer Disease. JAMA 281:1401–1406PubMedCrossRefGoogle Scholar
  19. 19.
    Mesulam M, Shaw P, Mash D, Weintraub S (2004) Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 55:815–828PubMedCrossRefGoogle Scholar
  20. 20.
    Goekoop R, Scheltens P, Barkhof F, Rombouts SA (2006) Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation—a pharmacological fMRI study. Brain 129:141–157PubMedCrossRefGoogle Scholar
  21. 21.
    Bartus RT, Dean RL, Beer C, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417PubMedCrossRefGoogle Scholar
  22. 22.
    Conner JM, Culberson A, Packowski C, Chiba AA, Tuszynski MH (2003) Lesions of the Basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning. Neuron 38:678–680CrossRefGoogle Scholar
  23. 23.
    Kilgard MP, Merzenich M (1998) Cortical map reorganization enabled by nucleus basalis activity. Science 279:1714–1718PubMedCrossRefGoogle Scholar
  24. 24.
    Drachman DA (1974) Human memory and the cholinergic system. Arch Neurol 30:113–121PubMedGoogle Scholar
  25. 25.
    Sarter M, Hasselmo ME, Bruno J, Givens B (2005) Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Rev 48:98–111PubMedCrossRefGoogle Scholar
  26. 26.
    Witte EA, Davidson MC, Marocco RT (1997) Effects of altering brain cholinergic activity on covert orienting of attention: comparison of monkey and human performance. Psychopharmacology 132:324–334PubMedCrossRefGoogle Scholar
  27. 27.
    Everitt BJ, Robbins TW (1997) Central cholinergic systems and cognition. Annu Rev Psychol 48:649–684PubMedCrossRefGoogle Scholar
  28. 28.
    Warburton EC, et al. (2003) Cholinergic neurotransmission is essential for perirhinal cortical plasticity and recognition memory. Neuron 38:987–996PubMedCrossRefGoogle Scholar
  29. 29.
    Assal F, Cummings JL (2002) Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 15:445–450PubMedCrossRefGoogle Scholar
  30. 30.
    Mesulam MM, Geula C (1992) Overlap between acetylcholinesterase-rich and choline acetyltransferase-positive (cholinergic) axons in human cerebral cortex. Brain Res 577:112–120PubMedCrossRefGoogle Scholar
  31. 31.
    Perry EK, Perry RH, Blessed G, Tomlinson BE (1977) Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1:189PubMedCrossRefGoogle Scholar
  32. 32.
    Iyo M, et al. (1997) Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer’s disease. Lancet 349:1805–1809PubMedCrossRefGoogle Scholar
  33. 33.
    Kuhl DE, et al. (1999) In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease [see comments]. Neurology 52:691–699PubMedGoogle Scholar
  34. 34.
    Shinotoh H, et al. (2000) Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography. Alzheimer Dis Assoc Disord 14:S114–S118PubMedCrossRefGoogle Scholar
  35. 35.
    Bohnen NI, et al. (2005) Cognitive correlates of alterations in acetylcholinesterase in Alzheimer’s disease. Neurosci Lett 380:127–132PubMedCrossRefGoogle Scholar
  36. 36.
    Tanaka N, et al. (2001) Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[(11)C]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for Alzheimer’s disease. J Cereb Blood Flow Metab 21:295–306PubMedCrossRefGoogle Scholar
  37. 37.
    Herholz K, et al. (2004) In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 21:136–143PubMedCrossRefGoogle Scholar
  38. 38.
    Bohnen NI, et al. (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745–1748PubMedCrossRefGoogle Scholar
  39. 39.
    Rinne JO, et al. (2003) Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease. J Neurol Neurosurg Psychiatry 74:113–115PubMedCrossRefGoogle Scholar
  40. 40.
    Herholz K, Weisenbach S, Kalbe E, Diederich NJ, Heiss WD (2005) Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport 16:1431–1434PubMedCrossRefGoogle Scholar
  41. 41.
    Eggers C, Herholz K, Kalbe E, Heiss WD (2006) Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease. Neurosci Lett 408:46–50PubMedCrossRefGoogle Scholar
  42. 42.
    Corder EH, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261:921–923 (see comments)PubMedCrossRefGoogle Scholar
  43. 43.
    Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA (2000) Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 48:391–395PubMedCrossRefGoogle Scholar
  44. 44.
    Bohnen NI, et al. (2005) Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 76:315–319PubMedCrossRefGoogle Scholar
  45. 45.
    Kaasinen V, et al. (2002) Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer’s disease. J Clin Psychopharmacol 22:615–620PubMedCrossRefGoogle Scholar
  46. 46.
    Shinotoh H, et al. (2001) Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 56:408–410PubMedGoogle Scholar
  47. 47.
    Carson RE, Kiesewetter DO, Jagoda E, Der MG, Herscovitch P, Eckelman WC (1998) Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: control and competition studies. J Cereb Blood Flow Metab 18:1130–1142PubMedCrossRefGoogle Scholar
  48. 48.
    Court J, Clementi F (1995) Distribution of nicotinic subtypes in human brain. Alzheimer Dis Assoc Disord 9:6–14PubMedCrossRefGoogle Scholar
  49. 49.
    Sabbagh MN, et al. (1998) Correlation of nicotinic binding with neurochemical markers in Alzheimer’s disease. J Neural Transm 105:709–717PubMedCrossRefGoogle Scholar
  50. 50.
    Nordberg A, et al. (1990) Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm Park Dis Dement Sect 2:215–224PubMedCrossRefGoogle Scholar
  51. 51.
    Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B (1995) Kinetic analysis of regional (S)(−)11C-nicotine binding in normal and Alzheimer brains—in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 9:21–27PubMedCrossRefGoogle Scholar
  52. 52.
    Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A (2006) PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease. Psychopharmacology (Berl) 188:509–520CrossRefGoogle Scholar
  53. 53.
    Marutle A, Warpman U, Bogdanovic N, Lannfelt L, Nordberg A (1999) Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation. J Neurochem 72:1161–1169PubMedCrossRefGoogle Scholar
  54. 54.
    Svensson AL, Warpman U, Hellstrom-Lindahl E, Bogdanovic N, Lannfelt L, Nordberg A (1997) Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Neurosci Lett 232:37–40PubMedCrossRefGoogle Scholar
  55. 55.
    Nordberg A, et al. (1997) Imaging of nicotinic and muscarinic receptors in Alzheimer’s disease: effect of tacrine treatment. Dement Geriatr Cogn Disord 8:78–84PubMedGoogle Scholar
  56. 56.
    Eriksdotter Jonhagen M, et al. (1998) Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 9:246–257PubMedCrossRefGoogle Scholar
  57. 57.
    Rinne JO, Myllykyla TP, Lonnberg P, Marjamaki P (1991) A postmortem study of brain nicotinic receptors in Parkinson’s disease and Alzheimer’s disease. Brain Res 547:167–170PubMedCrossRefGoogle Scholar
  58. 58.
    Pimlott SL, et al. (2004) Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[(125)I]-A-85380. Neuropsychopharmacology 29:108–116PubMedCrossRefGoogle Scholar
  59. 59.
    Perry EK, et al. (1995) Alteration in nicotine binding sites in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease: possible index of early neuropathology. Neuroscience 64:385–395PubMedCrossRefGoogle Scholar
  60. 60.
    Schmaljohann J, et al. (2004) Imaging of central nAChReceptors with 2-[18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer’s disease. Appl Radiat Isot 61:1235–1240PubMedCrossRefGoogle Scholar
  61. 61.
    Zubieta JK, et al. (2001) Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. Synapse 39:275–287PubMedCrossRefGoogle Scholar
  62. 62.
    Cohen RM, Carson RE, Filbey F, Szczepanik J, Sunderland TS (2006) Age and APOE-epsilon4 genotype influence the effect of physostigmine infusion on the in-vivo distribution volume of the muscarinic-2-receptor dependent tracer [18F]FP-TZTP. Synapse 60: 86–92PubMedCrossRefGoogle Scholar
  63. 63.
    Cohen RM, et al. (2003) Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. Synapse 49:150–156PubMedCrossRefGoogle Scholar
  64. 64.
    Nordberg A, Alafuzoff I, Winblad B (1992) Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 31:103–111PubMedCrossRefGoogle Scholar
  65. 65.
    Sparks D (1989) Aging and Alzheimer’s disease. Altered cortical serotonergic binding. Arch Neurol 46:138–140PubMedGoogle Scholar
  66. 66.
    Cheng AV, et al. (1991) Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer’s and Parkinson’s diseases. J Neurol Sci 106:50–55PubMedCrossRefGoogle Scholar
  67. 67.
    Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Bloom SR, Corsellis JA (1984) Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 43:1574–1581PubMedCrossRefGoogle Scholar
  68. 68.
    Cross AJ, et al. (1984) Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer-type. J Neurol Sci 64:109–117PubMedCrossRefGoogle Scholar
  69. 69.
    Blin J, et al. (1993) Loss of brain 5-HT2 receptors in Alzheimer’s disease. In vivo assessment with positron emission tomography and [18F]setoperone. Brain 116:497–510PubMedCrossRefGoogle Scholar
  70. 70.
    Meltzer CC, et al. (1999) PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry 156: 1871–1878PubMedGoogle Scholar
  71. 71.
    Meltzer CC, et al. (1998) Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res 813:167–171PubMedCrossRefGoogle Scholar
  72. 72.
    Sheline YI, Mintun MA, Moerlein SM, Snyder AZ (2002) Greater loss of 5-HT(2A) receptors in midlife than in late life. Am J Psychiatry 159:430–435PubMedCrossRefGoogle Scholar
  73. 73.
    Rosier A, et al. (1996) Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Res 68:11–22PubMedCrossRefGoogle Scholar
  74. 74.
    Kepe V, et al. (2006) Serotonin 1A receptors in the living brain of Alzheimer’s disease patients. Proc Natl Acad Sci USA 103:702–707PubMedCrossRefGoogle Scholar
  75. 75.
    Reiman EM, et al. (1996) Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334:752–758PubMedCrossRefGoogle Scholar
  76. 76.
    Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42:85–94PubMedCrossRefGoogle Scholar
  77. 77.
    Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropath Appl Neurobiol 14:39–44Google Scholar
  78. 78.
    Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346:205–230PubMedCrossRefGoogle Scholar
  79. 79.
    Katsurabayashi S, Kubota H, Tokutomi N, Akaike N (2003) A distinct distribution of functional presynaptic 5-HT receptor subtypes on GABAergic nerve terminals projecting to single hippocampal CA1 pyramidal neurons. Neuropharmacology 44:1022–1030PubMedCrossRefGoogle Scholar
  80. 80.
    Dillon KA, Gross-Isseroff R, Israeli M, Biegon A (1991) Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: effects of age and alcohol. Brain Res 554:56–64PubMedCrossRefGoogle Scholar
  81. 81.
    Hall H, et al. (1997) Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res 745:96–108PubMedCrossRefGoogle Scholar
  82. 82.
    Pazos A, Probst A, Palacios JM (1987) Serotonin receptors in the human brain-III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 21:97–122PubMedCrossRefGoogle Scholar
  83. 83.
    Ohyama M, et al. (1999) Preserved benzodiazepine receptors in Alzheimer’s disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med 13:309–315PubMedCrossRefGoogle Scholar
  84. 84.
    Meyer M, Koeppe RA, Frey KA, Foster NL, Kuhl DE (1995) Positron emission tomography measures of benzodiazepine binding in Alzheimer’s disease. Arch Neurol 52:314–317PubMedGoogle Scholar
  85. 85.
    Barg J, et al. (1993) Opioid receptor density changes in Alzheimer amygdala and putamen. Brain Res 632:209–215PubMedCrossRefGoogle Scholar
  86. 86.
    Hiller JM, Itzhak Y, Simon EJ (1987) Selective changes in mu, delta and kappa opioid receptor binding in certain limbic regions of the brain in Alzheimer’s disease patients. Brain Res 406:17–23PubMedCrossRefGoogle Scholar
  87. 87.
    Tariot PN, Sunderland T, Weingartner H, Murphy D, Cohen MR, Cohen RM (1986) Naloxone and Alzheimer’s disease. Cognitive and behavioral effects of a range of doses. Arch Gen Psychiatry 43:727–732PubMedGoogle Scholar
  88. 88.
    Cohen RM, Andreason PJ, Doudet DJ, Carson RE, Sunderland T (1997) Opiate receptor avidity and cerebral blood flow in Alzheimer’s disease. J Neurol Sci 148:171–180PubMedCrossRefGoogle Scholar
  89. 89.
    Hendry SH, Schwark HD, Jones EG, Yan J (1987) Numbers and proportions of GABA-immunoreactive neurons in different areas of monkey cerebral cortex. J Neurosci 7:1503–1519PubMedGoogle Scholar
  90. 90.
    Terry RD, Katzman R (1983) Senile dementia of the Alzheimer type. Ann Neurol 14:497–506PubMedCrossRefGoogle Scholar
  91. 91.
    Shoghi-Jadid K, et al. (2005) Imaging β-amyloid fibrils in Alzheimer’s disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol 32:337–351PubMedCrossRefGoogle Scholar
  92. 92.
    Shoghi-Jadid K, Barrio J, Kepe V, Huang SC (2006) Exploring a mathematical model for the kinetics of beta-amyloid molecular imaging probes through a critical analysis of plaque pathology. Mol Imaging Biol 8:151–162PubMedCrossRefGoogle Scholar
  93. 93.
    Lockhart A (2006) Imaging Alzheimer’s disease pathology: one target, many ligands. Drug Discov Today 11:1093–1099PubMedCrossRefGoogle Scholar
  94. 94.
    Ye L, Morgenstern JL, Gee AD, Hong G, Brown J, Lockhart A (2005) Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem 280:23599–23604PubMedCrossRefGoogle Scholar
  95. 95.
    Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF (2004) Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer’s disease. Brain Res 1025:98–105PubMedCrossRefGoogle Scholar
  96. 96.
    Lockhart A, et al. (2005) Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer’s disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem 280:7677–7684PubMedCrossRefGoogle Scholar
  97. 97.
    Agdeppa ED, et al. (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease. J Neurosci 21:1–5Google Scholar
  98. 98.
    Klunk WE, et al. (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain. J Neurosci 25:10598–10606PubMedCrossRefGoogle Scholar
  99. 99.
    Toyama H, et al. (2005) PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 32:593–600PubMedCrossRefGoogle Scholar
  100. 100.
    Klunk WE, et al. (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 55:306–319PubMedCrossRefGoogle Scholar
  101. 101.
    Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740–2754PubMedCrossRefGoogle Scholar
  102. 102.
    Klunk WE, et al. (2003) The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23:2086–2092PubMedGoogle Scholar
  103. 103.
    Bacskai BJ, et al. (2003) Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA 100:12462–12467PubMedCrossRefGoogle Scholar
  104. 104.
    Engler H, et al. (2006) Two-year follow-up of amyloid deposition in patients with Alheimer’s disease. Brain 129:2856–2866PubMedCrossRefGoogle Scholar
  105. 105.
    Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR (2000) “Preclinical” AD revisited: neuropathology of cognitively normal older adults. Neurology 55:370–376PubMedGoogle Scholar
  106. 106.
    Hyman BT, Marzloff K, Arriagada PV (1993) The lack of accumulation of senile plaques or amyloid burden in Alzheimer’s disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 52:594–600PubMedGoogle Scholar
  107. 107.
    Lopresti BJ, et al. (2005) Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46:1959–1972PubMedGoogle Scholar
  108. 108.
    Archer HA, et al. (2006) Amyloid load and cerebral atrophy in Alzheimer’s disease: an 11C-PIB positron emission tomography study. Ann Neurol 60:145–147PubMedCrossRefGoogle Scholar
  109. 109.
    Logan J, et al. (1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740–747PubMedGoogle Scholar
  110. 110.
    Mintun MA, et al. (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446–452PubMedCrossRefGoogle Scholar
  111. 111.
    Ono M, et al. (2003) 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer’s disease. Nucl Med Biol 30:565–571PubMedCrossRefGoogle Scholar
  112. 112.
    Verhoeff NP, et al. (2004) In-vivo imaging of Alzheimer disease beta-amyloic with [11C]SB-13 PET. Am J Geriatr Psychiatry 12:584–595PubMedCrossRefGoogle Scholar
  113. 113.
    Ichise M, Meyer JH, Yonekura Y (2001) An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 42:755–763PubMedGoogle Scholar
  114. 114.
    Shoghi-Jadid K, et al. (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10:24–35PubMedCrossRefGoogle Scholar
  115. 115.
    Smid LM, et al. (2006) The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol 16:124–130PubMedCrossRefGoogle Scholar
  116. 116.
    Small GW, et al. (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652–2663PubMedCrossRefGoogle Scholar
  117. 117.
    Agdeppa ED, et al. (2003) In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer’s brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. Neuroscience 117:723–730PubMedCrossRefGoogle Scholar
  118. 118.
    Bauer M, et al. (2006) A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer’s disease. Clin Pharmacol Ther 80:216–227PubMedCrossRefGoogle Scholar
  119. 119.
    Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45:358–368PubMedCrossRefGoogle Scholar
  120. 120.
    Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58:1395–1402PubMedCrossRefGoogle Scholar
  121. 121.
    Schonheit B, Zarski R, Ohm TG (2004) Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol Aging 25:697–711PubMedCrossRefGoogle Scholar
  122. 122.
    Mitchell T, et al. (2002) Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer’s disease. Ann Neurol 51:182–189PubMedCrossRefGoogle Scholar
  123. 123.
    Okamura N, et al. (2005) Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer’s disease. J Neurosci 25:10857–10862PubMedCrossRefGoogle Scholar
  124. 124.
    Chang YS, et al. (2006) Synthesis and evaluation of benzothiophene derivatives as ligands for imaging beta-amyloid plaques in Alzheimer’s disease. Nucl Med Biol 33:811–820PubMedCrossRefGoogle Scholar
  125. 125.
    Chandra R, Kung MP, Kung HF. (2006) Design, synthesis, and structure–activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett 16:1350–1352PubMedCrossRefGoogle Scholar
  126. 126.
    Ono M, et al. (2006) Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer’s disease brains. J Med Chem 49:2725–2730PubMedCrossRefGoogle Scholar
  127. 127.
    Suemoto T, et al. (2004) In vivo labeling of amyloid with BF-108. Neurosci Res 48:65–74PubMedCrossRefGoogle Scholar
  128. 128.
    Zeng F, et al. (2006) Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging beta-amyloid in Alzheimer’s disease. Bioorg Med Chem Lett 16:3015–3018PubMedCrossRefGoogle Scholar
  129. 129.
    Kreutzberg G (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312–318PubMedCrossRefGoogle Scholar
  130. 130.
    Cagnin A, et al. (2001) In-vivo measurement of activated microglia in dementia. Lancet 358:461–467PubMedCrossRefGoogle Scholar
  131. 131.
    Zakzanis KK (1998) Quantitative evidence for neuroanatomic and neuropsychological markers in dementia of the Alzheimer’s type. J Clin Exp Neuropsychol 20:259–269PubMedCrossRefGoogle Scholar
  132. 132.
    Zakzanis KK, Graham SJ, Campbell Z (2003) A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer’s type: a neuroimaging profile. Neuropsychol Rev 13:1–18PubMedCrossRefGoogle Scholar

Copyright information

© Academy of Molecular Imaging 2007

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioral NeurosciencesCedars-Sinai Medical CenterLos AngelesUSA
  2. 2.S. Mark Taper Foundation Imaging DepartmentCedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations